1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cough

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Cough in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barberà, JA; Casas, A; Chung, KF; Gabrijelcic, J; Rabinovich, RA; Roca, J; Rodríguez-Roisin, R	1

Trials

1 trial(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cough

Article	Year
Formoterol protects against platelet-activating factor-induced effects in asthma. The European respiratory journal, 2004, Volume: 23, Issue:1 Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Airway Resistance; Asthma; Cough; Cross-Over Studies; Double-Blind Method; Dyspnea; Ethanolamines; Female; Flushing; Formoterol Fumarate; Humans; Male; Neutropenia; Platelet Activating Factor; Pulmonary Circulation; Pulmonary Gas Exchange; Ventilation-Perfusion Ratio	2004

Article

Year

Formoterol protects against platelet-activating factor-induced effects in asthma.

The European respiratory journal, 2004, Volume: 23, Issue:1

Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Airway Resistance; Asthma; Cough; Cross-Over Studies; Double-Blind Method; Dyspnea; Ethanolamines; Female; Flushing; Formoterol Fumarate; Humans; Male; Neutropenia; Platelet Activating Factor; Pulmonary Circulation; Pulmonary Gas Exchange; Ventilation-Perfusion Ratio

2004